Cabot Corporation $CBT Shares Sold by Earnest Partners LLC

Key Points

• Earnest Partners LLC trimmed its position in Cabot by 1.2% in Q3, selling 39,783 shares and leaving it with 3,189,738 shares — roughly a 6.0% stake valued at about $242.6 million.
• Cabot reported Q earnings of $1.53 EPS (beating estimates) on $849 million revenue (below expectations), set FY2026 guidance of 6.000–6.500 EPS, and declared a quarterly dividend of $0.45 (annualized yield 2.6%).
• Analyst coverage is mixed with a consensus rating of Hold and an average price target of $73.75, ranging from a $54 underweight (JPMorgan) to an $85 buy (Jefferies).

Earnest Partners LLC reduced its holdings in shares of Cabot Corporation (NYSE:CBT - Free Report) by 1.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,189,738 shares of the specialty chemicals company's stock after selling 39,783 shares during the period. Cabot comprises 1.1% of Earnest Partners LLC's investment portfolio, making the stock its 21st largest holding. Earnest Partners LLC owned approximately 6.00% of Cabot worth $242,580,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CBT. Smartleaf Asset Management LLC increased its position in shares of Cabot by 598.0% during the third quarter. Smartleaf Asset Management LLC now owns 349 shares of the specialty chemicals company's stock worth $27,000 after acquiring an additional 299 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in shares of Cabot in the second quarter valued at $28,000. Hantz Financial Services Inc. boosted its holdings in Cabot by 227.5% in the third quarter. Hantz Financial Services Inc. now owns 429 shares of the specialty chemicals company's stock valued at $33,000 after purchasing an additional 298 shares during the period. Geneos Wealth Management Inc. grew its stake in Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 364 shares in the last quarter. Finally, Bayforest Capital Ltd acquired a new position in Cabot during the 3rd quarter worth $46,000. Hedge funds and other institutional investors own 93.18% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CBT shares. UBS Group increased their price target on Cabot from $74.00 to $81.00 and gave the company a "neutral" rating in a research report on Thursday, February 5th. Weiss Ratings reissued a "hold (c-)" rating on shares of Cabot in a research report on Monday, December 29th. Jefferies Financial Group restated a "buy" rating and set a $85.00 target price on shares of Cabot in a research note on Wednesday, February 4th. JPMorgan Chase & Co. reduced their target price on shares of Cabot from $75.00 to $54.00 and set an "underweight" rating on the stock in a report on Friday, November 28th. Finally, Mizuho set a $75.00 price target on shares of Cabot and gave the stock a "neutral" rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $73.75.

Cabot Stock Up 0.9%

Cabot stock opened at $69.49 on Friday. The stock has a market cap of $3.63 billion, a PE ratio of 12.17, a P/E/G ratio of 9.16 and a beta of 0.86. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.67 and a quick ratio of 1.09. The stock's fifty day moving average is $73.13 and its two-hundred day moving average is $71.01. Cabot Corporation has a 1-year low of $58.33 and a 1-year high of $84.89.

Cabot (NYSE:CBT - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The specialty chemicals company reported $1.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.13. Cabot had a return on equity of 22.82% and a net margin of 8.62%.The business had revenue of $849.00 million during the quarter, compared to analysts' expectations of $889.11 million. During the same period in the prior year, the firm posted $1.76 EPS. The business's quarterly revenue was down 11.1% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.000-6.500 EPS. On average, sell-side analysts expect that Cabot Corporation will post 7.57 EPS for the current fiscal year.

Cabot Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 13th. Investors of record on Friday, February 27th were issued a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Friday, February 27th. Cabot's dividend payout ratio is 31.52%.

Cabot Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

Want to see what other hedge funds are holding CBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabot Corporation (NYSE:CBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.